Assuntos
Doenças das Aves/virologia , Infecções por Coronavirus/veterinária , Vírus da Bronquite Infecciosa/classificação , Filogenia , Animais , Doenças das Aves/epidemiologia , Aves , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/virologia , Evolução Fatal , Vírus da Bronquite Infecciosa/isolamento & purificação , Reino Unido/epidemiologiaAssuntos
Galinhas , Infecções por Coronavirus/veterinária , Vírus da Bronquite Infecciosa/genética , Vírus da Bronquite Infecciosa/isolamento & purificação , Doenças das Aves Domésticas/virologia , Animais , Infecções por Coronavirus/virologia , Genótipo , RNA Viral/análise , RNA Viral/genética , RNA Viral/isolamento & purificação , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Reação em Cadeia da Polimerase Via Transcriptase Reversa/veterinária , Escócia , Especificidade da EspécieAssuntos
Galinhas , Infecções por Coronavirus/veterinária , Vírus da Bronquite Infecciosa/isolamento & purificação , Doenças das Aves Domésticas/epidemiologia , Animais , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , DNA Viral/análise , Vírus da Bronquite Infecciosa/classificação , Itália , Filogenia , Doenças das Aves Domésticas/diagnóstico , Reação em Cadeia da Polimerase Via Transcriptase Reversa/veterinária , Sorotipagem , Reino UnidoRESUMO
Fertile turkey eggs after 24 days of incubation were vaccinated in ovo with a commercial live attenuated subtype A avian pneumovirus (APV) vaccine. Hatchability was not adversely affected. When a high dose (10 times maximum commercial dose) of vaccine was tested in maternal antibody negative (MA-) eggs, mild clinical signs developed in a small proportion of the poults for 1-4 days only. Post-vaccination antibody titres at 3 weeks of age were significantly higher than those seen when the same dose was administered by eyedrop or spray at day-old. A low dose (end of shelf-life titre) of vaccine given to MA- eggs did not cause disease and vaccinated poults were 100% protected against virulent APV challenge at 3 or 5 weeks of age. Post-vaccination antibody titres reached significant levels at 3 weeks of age, whereas those from MA- poults vaccinated by spray at day-old with a similar low dose did not. In a 'worst-case' scenario, maternal antibody positive (MA+) poults vaccinated in ovo with the low dose were still 77% protected against clinical disease, despite lack of seroconversion. The recommended commercial dose of vaccine given to MA- eggs in ovo induced 100% protection against virulent APV challenge for up to 14 weeks of age, even though post-vaccination antibody titres had dropped to insignificant levels at this age. In ovo vaccination with a mixture of the recommended commercial doses of live APV and Newcastle disease (ND) vaccines had no detrimental affect on the efficacy of the APV vaccine. This is the first report of the successful use of an APV vaccine being given in ovo. The results indicate that for turkeys, in ovo vaccination with a live attenuated APV vaccine is safe and effective against virulent challenge and comparable with vaccination by conventional methods.